PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20881612-0	2010	Antiangiogenic and antimitotic effects of aspirin in hypoxia-reoxygenation modulation of the LOX-1-NADPH oxidase axis as a potential mechanism.	Aspirin	42-49	oxidized low density lipoprotein receptor 1	Homo sapiens	93-98	
23218405-0	2013	Ginkgo biloba extract and aspirin synergistically attenuate activated platelet-induced ROS production and LOX-1 expression in human coronary artery endothelial cells.	Aspirin	26-33	oxidized low density lipoprotein receptor 1	Homo sapiens	106-111	
23218405-1	2013	AIM: In the present study, we investigated whether the therapeutic dosages of Ginkgo biloba extract (EGb) and Aspirin (ASP) might synergistically suppress oxidative stress through regulating the expressions of LOX-1 and phosphorylated p38MAPK (p-p38MAPK) in human coronary artery endothelial cells (HCAECs) ex vivo.	Aspirin	110-117	oxidized low density lipoprotein receptor 1	Homo sapiens	210-215	
23218405-1	2013	AIM: In the present study, we investigated whether the therapeutic dosages of Ginkgo biloba extract (EGb) and Aspirin (ASP) might synergistically suppress oxidative stress through regulating the expressions of LOX-1 and phosphorylated p38MAPK (p-p38MAPK) in human coronary artery endothelial cells (HCAECs) ex vivo.	Aspirin	119-122	oxidized low density lipoprotein receptor 1	Homo sapiens	210-215	
23218405-11	2013	It appears that the synergistic effect of EGb and ASP may correlate with the inhibition of ROS production, LOX-1 expression and p38MAPK phosphorylation.	Aspirin	50-53	oxidized low density lipoprotein receptor 1	Homo sapiens	107-112	
23126503-0	2012	Comparative binding effects of aspirin and anti-inflammatory Cu complex in the active site of LOX-1.	Aspirin	31-38	oxidized low density lipoprotein receptor 1	Homo sapiens	94-99	
23126503-3	2012	In silico docking experiments in LOX-1 showed that aspirin does only weakly bind to LOX-1, while the complex binds with high affinity.	Aspirin	51-58	oxidized low density lipoprotein receptor 1	Homo sapiens	33-38	
23126503-3	2012	In silico docking experiments in LOX-1 showed that aspirin does only weakly bind to LOX-1, while the complex binds with high affinity.	Aspirin	51-58	oxidized low density lipoprotein receptor 1	Homo sapiens	84-89	
20881612-9	2010	Aspirin had no effect on endothelial nitric oxide synthase and canceled the transcriptional activation of the LOX-1 and p47(phox) subunit of NADPH oxidase.	Aspirin	0-7	oxidized low density lipoprotein receptor 1	Homo sapiens	110-115	
20881612-10	2010	Based on these data, we hypothesize that aspirin preserves the integrity of adherens junctions and thus blunts angiogenic response to HR through downregulation of LOX-1 and the LOX-1-mediated p47(phox) component of NADPH oxidase transcription, thus preventing NADPH oxidase assembly and function.	Aspirin	41-48	oxidized low density lipoprotein receptor 1	Homo sapiens	163-168	
20881612-10	2010	Based on these data, we hypothesize that aspirin preserves the integrity of adherens junctions and thus blunts angiogenic response to HR through downregulation of LOX-1 and the LOX-1-mediated p47(phox) component of NADPH oxidase transcription, thus preventing NADPH oxidase assembly and function.	Aspirin	41-48	oxidized low density lipoprotein receptor 1	Homo sapiens	177-182	
17538005-4	2007	In this study, we investigated the effect of aspirin and pravastatin on LOX-1 expression on plate-lets.	Aspirin	45-52	oxidized low density lipoprotein receptor 1	Homo sapiens	72-77	
17538005-10	2007	In other experiments, treatment with aspirin (1-10 mM) and pravastatin (1-5 microM) reduced platelet LOX-1 expression, with a synergistic effect of the combination of aspirin and pravastatin.	Aspirin	37-44	oxidized low density lipoprotein receptor 1	Homo sapiens	101-106	
17538005-10	2007	In other experiments, treatment with aspirin (1-10 mM) and pravastatin (1-5 microM) reduced platelet LOX-1 expression, with a synergistic effect of the combination of aspirin and pravastatin.	Aspirin	167-174	oxidized low density lipoprotein receptor 1	Homo sapiens	101-106	
17538005-15	2007	Furthermore, aspirin and pravastatin inhibit LOX-1 expression on platelets in part by favorably affecting ROS and NO release from activated platelets.	Aspirin	13-20	oxidized low density lipoprotein receptor 1	Homo sapiens	45-50	
15485683-0	2004	Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells.	Aspirin	0-7	oxidized low density lipoprotein receptor 1	Homo sapiens	33-38	
15485683-4	2004	We hypothesized that aspirin may interfere with LOX-1 expression and subsequent MMP activation.	Aspirin	21-28	oxidized low density lipoprotein receptor 1	Homo sapiens	48-53	
15485683-6	2004	Aspirin, in a dose- and time-dependent fashion, reduced ox-LDL-mediated LOX-1 expression (P<0.01).	Aspirin	0-7	oxidized low density lipoprotein receptor 1	Homo sapiens	72-77	
15485683-11	2004	CONCLUSION: These observations suggest that aspirin inhibits ox-LDL-mediated LOX-1 expression and interferes with the effects of ox-LDL in intracellular signaling (p38MAPK activation) and subsequent MMP-1 activity.	Aspirin	44-51	oxidized low density lipoprotein receptor 1	Homo sapiens	77-82